Advertisement

HIF prolyl hydroxylase inhibitor FG-4497 enhances mouse hematopoietic stem cell mobilization via VEGFR2/KDR

Kavita Bisht, Marion E. Brunck, Taichi Matsumoto, Crystal McGirr, Bianca Nowlan, Whitney Fleming, Thomas Keech, Graham Magor, Andrew C. Perkins, Julie Davies, Gail Walkinshaw, Lee Flippin, Ingrid G. Winkler and Jean-Pierre Levesque

Article Information

Citation 
vol. 3 no. 3 406-418
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted February 17, 2018
  • Accepted January 6, 2019
  • Published online February 7, 2019.


Contributors 
  • Kavita Bisht, 1Cancer Care and Biology Program, Mater Research Institute–The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia;
  • Marion E. Brunck, 1Cancer Care and Biology Program, Mater Research Institute–The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia;
  • Taichi Matsumoto, 1Cancer Care and Biology Program, Mater Research Institute–The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia;2Faculty of Pharmacological Sciences, Fukuoka University, Fukuoka, Japan;
  • Crystal McGirr, 1Cancer Care and Biology Program, Mater Research Institute–The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia;
  • Bianca Nowlan, 1Cancer Care and Biology Program, Mater Research Institute–The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia;
  • Whitney Fleming, 1Cancer Care and Biology Program, Mater Research Institute–The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia;
  • Thomas Keech, 1Cancer Care and Biology Program, Mater Research Institute–The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia;
  • Graham Magor, 1Cancer Care and Biology Program, Mater Research Institute–The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia;
  • Andrew C. Perkins, 1Cancer Care and Biology Program, Mater Research Institute–The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia;
  • Julie Davies, 1Cancer Care and Biology Program, Mater Research Institute–The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia;
  • Gail Walkinshaw, 3FibroGen, Inc., San Francisco, CA; and
  • Lee Flippin, 3FibroGen, Inc., San Francisco, CA; and
  • Ingrid G. Winkler, 1Cancer Care and Biology Program, Mater Research Institute–The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia;4Faculty of Medicine, The University of Queensland, Herston, QLD, Australia
  • Jean-Pierre Levesque, 1Cancer Care and Biology Program, Mater Research Institute–The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia;4Faculty of Medicine, The University of Queensland, Herston, QLD, Australia

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output